

sorbed amount of diazepam was not sufficient to counteract the elimination of the drug from blood, thus the plasma concentration declined steadily without the second peak.

The results of this study suggested a general implication for the drugs with biochemical characteristics similar to those of diazepam, such as temazepam and veralipride, which also exhibited double peaks of their blood concentration-time curves following a single dose^(9,10).

Enterohepatic circulation, like enterohepatic circulation, may exert some influence on the pharmacokinetic behavior of certain drugs. Its theoretical and practical significance calls for further investigation.

REFERENCES

1. Linnoila M, Korttila K, Mattila MJ. Effect of food and repeated injection on serum diazepam levels. *Acta Pharmacol Toxicol* 1975; **36**: 181-6.
2. Eustace PW, Hailey DW, Cox AG, Baird ES. Biliary excretion of diazepam in man. *Br J Anaesth* 1975; **47**: 983-5.
3. Korttila K, Kangas L. Unchanged protein binding and the increase of serum diazepam levels after food intake. *Acta Pharmacol Toxicol* 1977; **40**: 241-6.
4. Arnold E. A simple method for determining diazepam and its major metabolites in biological fluids; application in bioavailability studies. *Acta Pharmacol Toxicol* 1975; **36**: 335-52.
5. Brodie RR, Chasseaud LF, Taylor T. High-performance liquid

chromatographic determination of benzodiazepines in human plasma. *J Chromatogr* 1978; **150**: 361-6.

6. Miller R. Pharmacokinetics and bioavailability of ranitidine in humans. *J Pharm Sci* 1984; **73**: 1376-9.
7. Zhou HW, Shen JQ, Lu M, Liang WQ, Lin W, Zhao WH. Pharmacokinetic analysis of enterohepatic circulation of piroxicam in rabbits. *Acta Pharmacol Sin* 1992; **13**: 180-2.
8. Reitberg DP, Love SJ, Quercia GT, Zinny MA. Effect of food on nifedipine pharmacokinetics. *Clin Pharmacol Ther* 1987; **42**: 72-5.
9. Kroboth PD, Smith RB, Rault R, Silver MR, Sorkin MI, Pushchett JB, et al. Effects of end-stage renal disease and aluminum hydroxide on temazepam kinetics. *Clin Pharmacol Ther* 1985; **37**: 453-9.
10. Staveris S, Houin G, Tillement JP, Jamet G, Schneider M, Jung L, et al. Primary dose-dependent pharmacokinetic study of veralipride. *J Pharm Sci* 1985; **74**: 94-6.

地西洋血浆浓度的第二峰与肠胃循环

马越鸣, 孙瑞元

(皖南医学院药理教研室, 芜湖 241001, 中国)

摘要 兔 iv 地西洋 5 mg · kg⁻¹, 随即经胃管灌食物可使血药浓度出现明显的第二峰。对兔行胃造瘘术和胆总管造瘘术后, 第二峰消失。从胃液中检测到大量地西洋, 同期只有很少量的药物出现在胆汁中。结果提示, 地西洋在体内除肠肝循环外, 还可进行肠胃循环, 而第二峰的出现主要与后者有关。

关键词 地西洋; 药物动力学; 胃液; 胆汁; 胃造瘘术; 胆总管造瘘术

Effects of 4-[4''-(2'', 2'', 6'', 6''-tetramethyl-1''-piperidinyloxy) amino]-4'-demethylepipodophyllotoxin on immune function in mice

JIA Zheng - Ping, XIE Jing - Wen (Department of Pharmacy, General Hospital of Lanzhou Command of PLA, Lanzhou 730050, China)

FENG Pu, NIU Ji - Guo

(Department of Immunology, Gansu Institute of New Medicine, Lanzhou 730050, China)

ABSTRACT 4-[4''-(2'', 2'', 6'', 6''-Tetramethyl-1''-piperidinyloxy) amino]-4'-demethylepipodophyllotoxin (GP-7) 10-40 mg · kg⁻¹ ip daily for 7 d reduced the specific antibody formation of splenocytes, serum

agglutinin titer, and hemolysin HC_{50} in mice immunized with SRBC. GP-7 inhibited the footpad delayed hypersensitivity reaction and decreased the weights of spleen and thymus, but did not affect the phagocytic function of the peritoneal macrophages. *In vitro* the proliferation of mouse splenic lymphocytes activated by Con A was markedly inhibited by GP-7 in a concentration-dependent manner. At concentrations of $0.05 - 5 \text{ mg} \cdot \text{L}^{-1}$, the inhibition rates were 24 - 96%. These results suggested that GP-7 was an immunosuppressive agent.

KEY WORDS podophyllotoxin; immunosuppression; delayed hypersensitivity; hemolysins; T-lymphocytes; phagocytosis

Introduction of nitroxy radical moiety into some antitumor drugs, such as thiotepa, could result in compounds with pharmacological properties superior to those of the parent compounds^(1,2). A new spin-labeled derivative of podophyllotoxin, 4-[4''-(2'', 2'', 6'', 6''-tetramethyl-1''-piperidinyloxy) amino]-4'-demethylepipodophyllotoxin (GP-7), was synthesized in Lanzhou University, China⁽³⁾. In our previous works⁽⁴⁻⁶⁾, it was found that GP-7 markedly inhibited the growth of the transplanted mouse tumors sarcoma 180, solid carcinoma of ascitic hepatoma, leukemia P388 and Lewis lung carcinoma. *In vitro* it inhibited the proliferation of human gastric adenocarcinoma SGC-7901 and mouse leukemia L-1210 cells. Our recent works showed that GP-7 had a remarkable antitumor activity on bladder transitional cell carcinoma in patients by intratumor injection (data to be published). This experiment was to study the effects of GP-7 on immune function in mice.

MATERIALS

Drugs and chemicals GP-7 was synthesized by the Department of Chemistry, Lanzhou University. It was dissolved in 5% Tween-80 for ip in mice and in 20% Me_2SO (Demasorb) to a final concentration of 0.4% for the experiment *in vitro*. RPMI-1640 culture

medium (Gibco) containing 15% calf serum, penicillin 100 IU $\cdot \text{ml}^{-1}$ (Suzhou Second Pharmaceutical Factory) and streptomycin 100 $\mu\text{g} \cdot \text{ml}^{-1}$ (Shanghai No.4 Pharmaceutical Factory) was used as culture medium. Concanavalin A (Con A, Sigma).

Mice BALB c mice (either sex, aged 6-8 weeks, weighing $20 \pm 2 \text{ g}$) were bred in the Animal Center of Lanzhou Institute of Biological Products.

METHODS AND RESULTS

Effects of GP-7 on serum agglutinin titer and hemolysin in mice Forty BALB c mice randomized into 4 groups were injected ip with GP-7 0, 10, 20, and 40 $\text{mg} \cdot \text{kg}^{-1}$ daily for 7 d, and immunized with 3×10^8 sheep red blood cells (SRBC) ip on d 3. The serum samples from mice were collected on d 8. Agglutinin titer and hemolysin HC_{50} were measured by agglutination test and spectrophotometry⁽⁷⁾. Following the above treatment the body weights of mice in groups of GP-7 0, 10, 20, and 40 $\text{mg} \cdot \text{kg}^{-1}$ were 25.0 ± 2.1 , 25.4 ± 1.8 , 23.9 ± 2.3 , and 21.7 ± 2.3 ($P < 0.01$ vs 0 $\text{mg} \cdot \text{kg}^{-1}$). GP-7 decreased the serum agglutinin titer and hemolysin HC_{50} in mice in a dose-dependent manner (Tab 1).

Tab 1. Effects of GP-7 ip 7 d on serum agglutinin and hemolysin in mice immunized with SRBC. $n=10$, $\bar{x} \pm s$, *** $P < 0.01$ vs vehicle.

GP-7/ $\text{mg} \cdot \text{kg}^{-1} \cdot \text{d}^{-1}$	Agglutinin titer	Hemolysin HC_{50}
0 (vehicle)	508.3 ± 1.4	580 ± 93
10	381.2 ± 1.4	$441 \pm 58^{**}$
20	$195.0 \pm 1.9^{***}$	$319 \pm 46^{***}$
40	$40.9 \pm 1.4^{***}$	$148 \pm 5^{***}$

Effect of GP-7 on specific antibody formation of splenocytes in mice The mice were treated with the same program. On d 8 the spleens were excised after cervical dislocation, and the single cell suspensions were prepared by grinding gently against sterile

less steel mesh. The specific antibody formation of splenocytes in mice was assayed by spectrophotometry⁽⁷⁾. Results showed that GP-7 inhibited the specific antibody formation of splenocytes in mice. The absorbances (at 540 nm) in the groups of GP-7 0, 10, 20, and 40 mg·kg⁻¹ were 0.83±0.17, 0.72±0.14, 0.53±0.17, and 0.49±0.12 (n=10, P<0.01 vs 0 mg·kg⁻¹).

Effect of GP-7 on delayed hypersensitivity (DH) in mice Four groups of BALB c mice were treated ip with GP-7 0, 10, 20, and 40 mg·kg⁻¹ daily for 7 d (d 1-7), immunized with 2×10⁸ SRBC sc on d 3, challenged with 1×10⁸ SRBC injected sc to the right footpad on d 8; a same volume of saline was injected sc to left footpad as control. DH was assayed by measuring the thickness difference between right and left footpads with a micrometer 24 h after challenge. Results showed that the DH induced with SRBC was inhibited by GP-7 10-40 mg·kg⁻¹ ip for 7 d. The thickness differences between their right and left footpads decreased by 37-70% (Tab 2).

Tab 2. Effect of GP-7 ip 7 d on footpad delayed hypersensitivity (DH) in BALB c mice immunized with SRBC. n=10, $\bar{x}\pm s$, **P<0.05, ***P<0.01 vs vehicle.

GP-7/ mg·kg ⁻¹ ·d ⁻¹	Thickness of pad/mm		Thickness difference/mm
	Right	Left	
0 (vehicle)	2.8±0.7	2.3±0.6	0.54±0.18
10	2.7±0.7	2.3±0.5	0.34±0.15**
20	2.5±0.5	2.3±0.6	0.23±0.11***
40	2.3±0.5	2.2±0.5	0.16±0.12***

Effect of GP-7 on proliferation of mouse splenic lymphocytes activated by Con A *in vitro* Splenocytes of 10 mice were prepared on ice and suspended in RPMI-1640 culture medium (2×10⁸ cells·ml⁻¹). the suspension was put into the wells of 24-wells culture

plates at 1 ml/well. GP-7 and Con A were added. Following the incubation in a 5% CO₂ incubator 37°C for 56 h, [³H]deoxythymidine ([³H]TdR) was added into the wells to a final concentration of 37 kBq·ml⁻¹. After incubation in a CO₂ incubator for another 16 h, the cells were harvested on glass fiber filters, and the incorporated radioactivity was determined by a FJ-2100 liquid scintillation counter. The proliferation of mouse splenic lymphocytes activated by Con A *in vitro* was inhibited 24-96% by GP-7 0.05-5 mg·L⁻¹ in a concentration-dependent manner (Tab 3).

Tab 3. Effect of GP-7 on proliferation of mouse splenic lymphocytes activated by Con A *in vitro*. n=6, $\bar{x}\pm s$, **P<0.05, ***P<0.01 vs control (GP-7 0 mg·L⁻¹, Con A 3 mg·L⁻¹).

GP-7/ mg·L ⁻¹	Con A/ mg·L ⁻¹	Radioactivity of [³ H]TdR in DNA/dpm
0	0	1 663±468
0	3	19 802±3721
0.05	3	15 114±2990**
0.5	3	6 087±932***
5	3	698±189***

Effect of GP-7 on peritoneal macrophage phagocytosis in mice After GP-7 ip for 7 d, the mouse was killed 1 h after ip 2% chicken RBC 1 ml. The cells in the peritoneal exudate were collected and examined (Giemsa stain, ×1000). No significant effect of GP-7 on the phagocytosis of peritoneal macrophages in mice was seen (Tab 4).

Effects of GP-7 on spleen and thymus weights in mice Forty BALB c mice randomized into 4 groups were injected ip with GP-7 0, 10, 20, and 40 mg·kg⁻¹ for 7 d. Their spleens and thymuses were excised after cervical dislocation and weighed. The results showed that the weights of spleen and thymus decreased by 17-55% and 34-85%, respectively after GP-7 (Tab 5).

Tab 4. Effect of GP-7 ip 7 d on peritoneal macrophage phagocytosis in mice. $n=10$, $\bar{x}\pm s$, $^*P > 0.05$ vs vehicle.

GP-7/ mg·kg ⁻¹ ·d ⁻¹	Phagocytosis/%	Phagocytic index
0 (vehicle)	46±6	0.86±0.12
10	48±6*	0.92±0.11*
20	39±8*	0.91±0.18*
40	42±7*	0.87±0.13*

Tab 5. Effects of GP-7 ip 7 d on spleen and thymus weights in mice. $n=10$, $\bar{x}\pm s$, $^{}P < 0.05$, $^{***}P < 0.01$ vs vehicle.**

GP-7/ mg·kg ⁻¹ ·d ⁻¹	Spleen wt/mg	Thymus wt/mg
0 (vehicle)	183±28	68±17
10	152±30**	45±16***
20	108±31***	21±6***
40	82±16***	10±3***

DISCUSSION

Our results showed that the new podophyllotoxin derivative, GP-7 markedly suppressed the humoral and cell-mediated immunities in mice, suggesting that podophyllotoxin and its congeners may turn out to be a new series in the immunosuppressive agents. It was known that most of cytotoxic antitumor agents, such as cyclophosphamide, had an immunosuppressive activity to a certain extent. The inhibitory effects of GP-7 on immune function may also be attributed to its cytotoxic effect. However, the exact mechanism remained to be further investigated.

REFERENCES

1 Emanuel NM, Konovalova NP, Djachkevskaya RF. Toxicity, antitumor activity, and pharmacokinetics of spin-labeled ThioTEPA analogs. *Cancer Treat Rep* 1976; **60**: 1605-9.
 2 Sosnovsky G, Paul BD. In the search for new anticancer drugs.

9. Synthesis and anticancer activity of spin-labeled analogues of N;N',N':N'',N'''-tri-1,2-ethanediyolphosphoric triamide and N;N',N':N'',N'''-tri-1,2-ethanediyolphosphorothioic triamide. *J Med Chem* 1984; **27**: 782-8.
 3 Chen YZ, Wang YG, Li JX, Tian X, Jia ZP, Zhang PY. Anticancer drugs II. Synthesis and biological evaluation of spin-labeled derivatives of podophyllotoxin. *Life Sci* 1989; **45**: 2569-77.
 4 Jia ZP, Zhang PY, Liang ZD, Wang YG, Chen YZ, Li JX, et al. Antitumor activity of 4-[4''-(2'', 2'', 6'', 6''-tetramethylpiperidinyloxy)amino]-4'-demethylepipodophyllotoxin *in vitro*. *Acta Pharmacol Sin* 1990; **11**: 549-53.
 5 Jia ZP, Zhang PY, Liang ZD. Effects of 4-[4''-(2'', 2'', 6'', 6''-tetramethyl-1''-piperidinyloxy) amino]-4'-demethylepipodophyllotoxin on the proliferation, clonal formation and DNA synthesis of L1210 cells *in vitro*. *Chin J Pharmacol Toxicol* 1991; **5**: 47-9.
 6 Jia ZP, Xie JW, Zhang PY, Liang ZD, Wang YG, Chen YZ. Antitumor activity of 4-[4''-(2'', 2'', 6'', 6''-tetramethylpiperidinyloxy) amino]-4'-demethylepipodophyllotoxin. *Chin J Pharmacol Bull* 1991; **7**: 304-7.
 7 陈敏珠. 体液免疫测定法. 见: 徐叔云, 卞如濂, 陈伟, 主编. 药理实验方法学. 第1版. 北京: 人民卫生出版社, 1991: 944-52.

4-[4''-(2'', 2'', 6'', 6''-四甲基哌啶氮氧自由基氨基)-4'-去甲表鬼臼毒素对小鼠免疫功能的影响

贾正平, 谢景文
 (兰州军区总医院药材科, 兰州730050, 中国)
 冯 璞, 牛继国
 (甘肃省新医药研究所免疫室, 兰州730050, 中国)

摘要 4-[4''-(2'', 2'', 6'', 6''-四甲基哌啶氮氧自由基氨基)-4'-去甲表鬼臼毒素(GP-7) 10-40 mg·kg⁻¹ ip 7 d, 降低小鼠脾细胞特异抗体的产生、血清IgG滴度和溶血素HC₅₀值, 抑制小鼠足垫迟发型超敏反应, 减轻小鼠脾和胸腺重量. 在体外, GP-7 0.5-5 mg·L⁻¹, 处理72 h, Con A刺激的小鼠脾淋巴细胞增殖率降低24-96%. GP-7对小鼠腹腔巨噬细胞吞噬功能无影响.

关键词 鬼臼毒素; 免疫抑制; 迟发型超敏反应; 溶血素类; T-淋巴细胞; 吞噬作用